Literature DB >> 9588916

The prognostic significance of tracheostomy in carcinoma of the larynx treated with radiotherapy and surgery for salvage.

R MacKenzie1, E Franssen, J Balogh, D Birt, R Gilbert.   

Abstract

PURPOSE: To determine retrospectively the prognostic significance of airway compromise necessitating tracheostomy in carcinoma of the larynx managed with radical radiotherapy and surgery for salvage (RRSS). METHODS AND MATERIALS: The charts of 270 patients managed with RRSS at the Toronto-Sunnybrook Regional Cancer Centre between June 1980 and December 1990 were reviewed. Airway compromise necessitating tracheostomy was documented in 26 patients prior to radiotherapy and 3 patients during radiotherapy. Of 29, 27 had T3T4 primaries. Patients have been followed for a median of 5 years.
RESULTS: Patients managed without tracheostomy had a 2-year disease-free survival of 74% compared to 41% for those managed with tracheostomy. The adverse impact of airway compromise was more marked in patients with glottic primaries (78% vs. 32%, p = 0.0001) than those with supraglottic primaries (64% vs. 47%, p = 0.18). Tracheostomy was identified in univariate analysis, but not in multivariate analysis, as having a statistically significant impact on local control and local-regional control. Radiotherapy controlled disease above the clavicles in 185 of 267 (69%) evaluable patients. 83% of isolated local-regional failures underwent salvage surgery. Among those managed without tracheostomy, ultimate local-regional control (LRC) was achieved in 161 (94%) of 172 glottic primaries and 54 (81%) of 67 supraglottic primaries. Among those managed with tracheostomy, ultimate LRC was achieved in 9 (69%) of 13 glottic primaries and 12 (80%) of 15 supraglottic primaries. In a subset analysis of 76 patients with T3T4 primaries, there was no statistically significant difference in larynx preservation, disease-free survival, or cause-specific survival between those managed with and without tracheostomy.
CONCLUSION: Airway compromise necessitating tracheostomy is an adverse prognostic factor in patients with carcinoma of the larynx. However, larynx preservation is possible in over 40% of those undergoing tracheostomy and radiotherapy with no compromise of cause-specific survival. The need for pretreatment tracheostomy should not rule out the possibility of RRSS.

Entities:  

Mesh:

Year:  1998        PMID: 9588916     DOI: 10.1016/s0360-3016(98)00030-3

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  5 in total

1.  Organ-preservation (chemo)radiotherapy for T4 laryngeal and hypopharyngeal cancer: is the effort worth?

Authors:  Abrahim Al-Mamgani; Arash Navran; Iris Walraven; Willen Hans Schreuder; Margot E T Tesselaar; Willem Martin C Klop
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-12-18       Impact factor: 2.503

2.  Non-surgical organ preservation strategies for locally advanced laryngeal tumors: what is the Italian attitude? Results of a national survey on behalf of AIRO and AIOM.

Authors:  D Alterio; P Franco; G Numico; L Licitra; M Cossu Rocca; A Ferrari; C Pinto; E G Russi; U Ricardi; B A Jereczek Fossa
Journal:  Med Oncol       Date:  2016-06-11       Impact factor: 3.064

3.  Induction chemotherapy in locally advanced pharyngolaryngeal cancers with stridor: is it feasible and safe?

Authors:  Vijay Maruti Patil; Vanita Noronha; Amit Joshi; Vamshi Muddu; Bhavesh Poladia; Bharat Chauhan; Kumar Prabhash; Devendra Arvind Chaukar; Pankaj Chatturvedi; Gouri Pantvaidya; Shashikant Juvekar; Anil D'cruz
Journal:  Chemother Res Pract       Date:  2012-08-12

4.  Preservation of organ function in head and neck cancer.

Authors:  Uta Tschiesner
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2012-12-20

5.  Persistent Tracheostomy after Organ Preservation Protocol in Patients Treated for Larynx and Hypopharynx Cancer.

Authors:  Carlos Miguel Chiesa Estomba; Frank Alberto Betances Reinoso; Virginia Martinez Villasmil; Maria Jesus González Cortés; Carmelo Santidrian Hidalgo
Journal:  Int Arch Otorhinolaryngol       Date:  2017-04-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.